FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to occupational pathology, and can be used for rehabilitation of workers with chronic occupational diseases of respiratory organs, namely, rhinopharyngitis, tracheobronchitis caused by exposure to harmful factors of titanium-magnesium production. That is ensured by medical examination of workers with respiratory disease - rhinopharyngitis, tracheobronchitis. Following clinical signs are detected: a grey nasal mucosa, dryness and thinning of the nasal mucosa; presence of crusts on the walls of nasal passages, enlarged nasal passages, congestive hyperaemia of pharyngeal posterior wall, back pharynx granularity, tonsil hyperplasia; asthenoneurotic syndrome; headaches; shortness of breath during physical activity. Reveal the presence of a moderate decrease of the volume flow when a front active rhinomanometry from 150 to 199 cm3/s and the content of dust particles at rhinocytoscopy more than 10 units in the field of view. Presence of a number of deviations of laboratory blood values from the physiological norm, namely increase of malondialdehyde by 20 % and more from the upper limit of norm; increase of lipids hydroperoxide by 20 % and more from upper limit of norm; antioxidant activity of plasma is lower by 20 % and more from lower limit of norm; immunoglobulin A is lower by 15 % and more from the lower limit of normal. After that, such workers undergo twice a year rehabilitation course of drug-induced therapy and complex physiotherapeutic exposure. 10 ml of Cytoflavin drug is injected intravenously drop by drop into 100-200 ml saline for 10 days. Broncho-Vaxom is administered 7 mg once day for 10 days with pause of 20 days for three months; Complevit preparation 1 tablet after meals once a day with course of 30 days. Nose is washed with the Polidexa with phenylephrine nasal spray in 1 injection 2 times a day in each nostril for 10 days. Chlorophyllipt preparation is also used in the form of alcoholic solution 1 % 15 ml per 1 l of water for nasal irrigation and throat rinsing 2 times a day. Additionally, starting from the second day of drug administration, the magnetic laser is exposed to a thorax by an apparatus with the following parameters: laser infrared radiation, up to 8 W; infrared radiation, 60 W; red radiation, 7 mW. Radiator of the apparatus is fixed directly on the skin. Exposure to laser radiation is performed at density of 5–10 mW/cm2, the magnetic field strength in range of 20–25 mT. Exposure to one field makes 1–2 minutes, total length of procedure does not exceed 20 minutes. Exposure is daily by course of 10 procedures in a combination with electrophoresis with calcium chloride solution 10 % intranasal daily also by course of 10 procedures. Electrophoresis is performed from the apparatus with direct current of 20 mA for 20 minutes. Before electrophoresis, the nose is washed with the Polydexa with phenylephrine nasal spray, and the Chlorophyllipt preparation is used after electrophoresis.
EFFECT: method provides effective rehabilitation, pronounced clinical effect, reduced frequency of exacerbations of the formed chronic pathology as a result of pathogenetically substantiated drug-induced and physiotherapeutic treatment due to anti-inflammatory, desensitising, local immunomodulatory action, higher antioxidant protection of respiratory mucosa, higher total body resistance.
1 cl, 3 tbl, 2 ex
